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ABSTRACT: Low and heterogeneous delivery of drugs and imaging agents to tumors results in decreased efficacy and poor imaging
results. Systemic delivery involves a complex interplay of drug properties and physiological factors, and heterogeneity in the tumor
microenvironment makes predicting and overcoming these limitations exceptionally difficult. Theoretical models have indicated that there
are four different classes of pharmacokinetic behavior in tissue, depending on the fundamental steps in distribution. In order to study these
limiting behaviors, we used multichannel fluorescence microscopy and stitching of high-resolution images to examine the distribution of
four agents in the same tumor microenvironment. A validated generic partial differential equation model with a graphical user interface
was used to select fluorescent agents exhibiting these four classes of behavior, and the imaging results agreed with predictions. BODIPY-FL
exhibited higher concentrations in tissue with high blood flow, cetuximab gave perivascular distribution limited by permeability, high
plasma protein and target binding resulted in diffusion-limited distribution for Hoechst 33342, and Integrisense 680 was limited by the
number of binding sites in the tissue. Together, the probes and simulations can be used to investigate distribution in other tumor models,
predict tumor drug distribution profiles, and design and interpret in vivo experiments. C© 2014 Wiley Periodicals, Inc. and the American
Pharmacists Association J Pharm Sci 103:3276–3286, 2014
Keywords: drug transport; imaging methods; in vivo/in vitro correlations (IVIVC); mathematical model; Krogh cylinder; fluorescence
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INTRODUCTION
Drug delivery and distribution in tumors is a complicated in-
terplay of local tumor physiology and drug properties. Under-
standing and being able to predict this distribution is im-
perative to developing new therapies, as poor uptake has
been shown to correlate with poor outcome in the clinic.1 Tu-
mor physiology is highly variable with gradients in oxygen,2
metabolic waste products,3 pH,4 differences in extracellu-
lar matrix composition,5,6 cell packing,7 interstitial pressure,8
multiple cell types,9 poor blood flow,10 increased and vari-
able permeability,11 and heterogeneous target concentrations12
among others. For drug properties, the dose, molecular
weight, charge,13 target affinity and specificity, shape (e.g.,
globular versus linear macromolecules14,15 or aspect ratio
in nanoparticles16), surface chemistry (e.g., nanoparticles17,18
and antibody drug conjugates19), lipophilicity,20 pKa, lo-
cal metabolism (e.g., antibody internalization), and systemic
(plasma) clearance impact distribution. Even more compli-
cated is that tissue physiology and drug property effects are
not independent. Increasing dose may have little effect if a
growth receptor is saturated,21 for example, but have a ma-
jor impact in another tumor or adjacent region with much
higher receptor concentration where many receptors remain
untargeted.
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Tumor distribution is equally important for imaging agent
development. Molecular imaging agents must reach their tar-
get to bind (e.g., radiolabeled ligands) or activate (e.g., protease
sensors22) for accurate measurements. The physiochemical
properties of the agent must allow the binding or activation to
dominate distribution, otherwise nonspecific mechanisms such
as membrane uptake may dictate the signal.23 The require-
ments are even higher for quantitative imaging agents. Here,
even if some of the target is exposed to the imaging agent,
the resulting image may not be correlated with the amount of
target.24–28 In many cases, the imaging time will have an im-
pact on the signal, such as fluorodeoxyglucose (FDG) that is
limited by blood flow at early times29 and glucose uptake and
metabolism at later times.30
Because of the complex interplay of factors determining dis-
tribution, often multiple animal experiments are conducted
with a variety of agents and variable results. This method
is time consuming and expensive, with no guarantee that
the models will mimic the clinical scenario. Mathematical
simulations are playing a larger role in determining local
distribution31–34; these models are capable of clearly identify-
ing the impact of various factors (e.g., drug lipophilicity, tumor
blood flow) on drug distribution using a fraction of the time and
cost of experimental investigations. Predictive physiologically
based pharmacokinetic (PBPK) models are increasingly able to
determine the organ level distribution for small molecules35–38
and biologics,39–41 and these methods are useful for predicting
the distribution in the clinic. However, assumptions that are
valid in healthy tissuemay fail in the tumormicroenvironment.
We have been developing partial differential equation (PDE)
models to accurately describe the distribution of molecules in
tumors.31,42
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Theoretical studies indicate that there are four major classes
of pharmacokinetic distribution in tumors depending on the
rate limiting step in uptake.42 Molecules can be classified by
(1) blood flow limitations, (2) extravasation limitations, (3) dif-
fusion limitations, or (4) local binding and/or metabolism limi-
tations, and these categories can be determined from the agent
and tissue properties.42 These classes are useful because they
allow predictions about the impact of tumor physiology on dis-
tribution. For example, changes in macromolecular permeabil-
ity would have no direct impact on a blood flow limited agent
but a major change in an extravasation-limited agent.
Here, we usemultichannel imagingwithin the same tumor to
look at different patterns of distribution. The variability within
and between tumorsmakes it difficult to parse out the impact of
drug properties versus the local microenvironment. Using mul-
tichannel imaging, several drugs and imaging agents can be
examined simultaneously in the same tumor to mitigate tumor
microenvironment effects. The PDE model was used to predict
the distribution of fourmolecules that displayed characteristics
of the different classes of pharmacokinetic distribution. The se-
lection criteria also ensured that these agents had different
fluorescence excitation and emission profiles so they could be
independently followed within the tumors. The model was also
used to determine the imaging time after injection, and image
analysis was performed to quantitatively compare the distribu-
tion with predictions.
BODIPY-FL was chosen as a representative blood flow lim-
ited molecule due to its low molecular weight and relatively
low plasma protein binding for a fluorophore. Cetuximab is a
chimeric monoclonal antibody used in the clinic to treat colon43
and head and neck cancer44; it was selected as a representa-
tive antibody, which are generally limited by extravasation.45
Hoechst 33258 was initially discovered and developed as an an-
tiparasitic drug,46 but both Hoechst dyes were quickly adopted
for fluorescence imaging given their cell permeability and
bright nuclear signal. Hoechst 33342 has been used in tumors to
track functional vessels,47,48 and its high plasma protein bind-
ing “buffers” the concentration within vessels so it is not de-
pleted along the length of a tumor capillary. High cell uptake
also allows it to quickly diffuse through endothelial cells, and
the large number of DNA binding sites prevents it from satu-
rating its target. Therefore, this agent is predicted to be limited
by diffusion in the tissue. Hoechst 33258 has similar properties
but is taken up by cells much slower than Hoechst 33342 even
though they only differ by a hydroxyl versus an ethoxy group.
Integrisense was originally developed as an "v$3 integrin in-
hibitor for osteoporosis,49 but high specificity and affinity for
its target made it an excellent imaging agent after conjugation
to a fluorophore.50
The distribution of these agents was studied in A-431
xenografts for several reasons. The high epidermal growth fac-
tor receptor (EGFR) expression in this line (∼4 million recep-
tors per cell) was predicted to give extravasation limited uptake
for cetuximab (versus a saturating dose that would be limited
by binding sites). The vasculature of this tumor is highly hetero-
geneous with some hypervascularized areas and other necrotic
regions, replicating the variable tumor physiology seen inmany
animal models and the clinic. A-431 xenografts also have low
"v$3 expression (∼104 receptors per cell51), ensuring that the
Integrisense 680 imaging agent would saturate its target and
therefore be binding site limited.
MATERIALS AND METHODS
Mathematical Model
The mathematical simulations were based on a previously pub-
lished model.42 Details can be found in the supplementary data
(Section 1), but briefly, it consists of nonlinear PDEs with axial
and radial gradients around a Krogh cylinder representation
of tumor vessels. Time-dependent mixed boundary conditions
determine the extravasation and depletion along the length of
the vessel, and diffusion across a pseudo-homogeneous tissue
with saturable binding and local metabolism dictates the tis-
sue distribution. Equations are solved using finite differences
in MATLAB (Mathworks), and a sparse Jacobian is specified to
reduce computation time. Parameterization is also challenging
with literature values often sparse and sometimes contradic-
tory, especially for small molecules where equilibrium values
are more readily available than kinetic rates. A table of param-
eters with references used in the predictions is listed in the
supplementary data (Table S1, Supporting Information).
Cell Lines and Imaging Agents
A-431 cells were obtained from ATCC (Manassas, Virginia).
Cetuximab (Bristol-Myers Squibb, Princeton, New Jersey) was
conjugated with Alexa Fluor 750 (Life Technologies, Eugene,
Oregon) according to the manufacturer’s instructions. Briefly,
1.75 molar equivalents of dye were added to a solution of ce-
tuximab (2 mg/mL) in 10% sodium bicarbonate and incubated
at room temperature for 1 h. The conjugate was purified using
800 :L of 5 g/50 mL water of Biogel P-6 gel, Fine (Bio-Rad,
Hercules, California; Cat. No. 150–4134) in Spin-X centrifuge
filter tubes (Corning, Corning, New York; Cat. No. 8160) with a
final degree of labeling of 1.4 dyes/antibody. Polyacrylamide gel
electrophoresis was used to verify no free dye remained after
purification. Anti-mouse CD31 (Biolegends, San Diego, Cali-
fornia; Cat. No. 102402) and anti-EGFR (R&D Systems, Min-
neapolis, Minnesota; Cat. No. AF231) antibodies were labeled
with Alexa Fluor 555 (Life Technologies) in a similar manner
except the molar ratio was 5 instead of 1.75 for a higher degree
of labeling as these antibodies were not injected in vivo. Inte-
grisense 680 (PerkinElmer, Waltham, Massachusetts), Hoechst
33342, Hoechst 33258, and BODIPY-FL propionic acid (Invit-
rogen, Grand Island, New York) were used without further
purification.
Plasma protein binding of Integrisense 680, Hoechst 33342
and 33258, and BODIPY-FL propionic acid were measured us-
ing a Rapid Equilibrium Dialysis (Thermo Scientific, Rockford,
Illinois) plate according to the manufacturer’s instructions.
Mouse plasma (Innovative Research, Novi, Michigan; Cat. No.
C57BL6) was mixed with either 20 :M of BODIPY FL, 50 :M
of Hoechst dye, or 1 :Mof Integrisense 680. After equilibration,
the buffer in each chamber was adjusted to 50/50mouse plasma
and PBS to eliminate effects of protein binding on fluorescence.
The signal was measured using either a SpectraMax M5 Mi-
croplate reader (Molecular Devices, Sunnyvale, California) or
Odyssey CLx (Licor, Lincoln, Nebraska).
In Vitro Experiments
Tomeasure the cellular uptake rate of Hoechst dyes in the pres-
ence of serum and at 37◦C, A-431 cells were plated overnight
in 96-well plates. Hoechst dyes were diluted with L-15 media
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(without phenol red) and 10% FBS to concentrations of 10
and 100 :g/mL each. A microplate reader maintained at 37◦C
was used to measure fluorescence (excitation 350 nm, emission
450 nm), and the signal was background subtracted using wells
with no cells. Experiments were conducted in triplicate, aver-
aging five wells each time.
The kinetic rates of cellular uptake were determined by us-
ing a two-compartment model to fit the experimental data (Fig.
S1, Supporting Information). Details are in the supplementary
data (Supplemental Section 1), but the probe was assumed to
cross the plasma membrane by passive diffusion52,53 into an
intracellular compartment and then transport to the nucleus
and bind the DNA. When combining with the PDE model, the
intracellular probe was considered immobile.
In Vivo Experiments
A-431 cells were used to grow tumor xenografts in 8–12
week old female nu/nu mice (Jackson Laboratory, Bar Harbor,
Maine). All experiments involving mice were conducted in com-
pliance with the University of Michigan University Committee
onUse andCare of Animals (UCUCA). The cells were harvested
using Trypsin–EDTA (0.05%), resuspended in PBS at a concen-
tration of 1.5 million cells/50 :L, and injected subcutaneously
in each hind limbwhile themouse (n= 16) was anesthetized us-
ing isoflurane at 2% and 1 L/min oxygen. When the longest axis
of the tumor was 5–10 mm, 0.2 nmol of Cetuximab and 2 nmol
of Integrisense 680 were injected intravenously 24 h before
euthanizing the mouse. 15 mg/kg of Hoechst 33342 or 33258
and 50 nmol of Bodipy FL were injected 3 h before and 2 min
before euthanizing, respectively. All injections were formulated
in 100–150 :L of phosphate-buffered saline. The tumors were
then resected along with the liver, snap frozen in optimal cut-
ting temperature (OCT) compound using isopentane cooled
with dry ice. The tumors and liver were sectioned into 6 :m
slices on a cryostat.
Slides were imaged using an upright Olympus FV1200 con-
focal microscope equipped with 405, 488, 543, 633, and 750 nm
laser lines. High-resolution images of the entire tumor were
created by stitching together individual images taken with
a 20× objective and a motorized stage. Because BODIPY-FL
was the only drug not bound to a target, these slides were
pretreated with ethyl-3-[3-dimethylaminopropyl] carbodiimide
(EDC) (Sigma–Aldrich, St. Louis, Missouri) to minimize wash-
out before imaging this channel. Seventy-five microliters of a
0.5 M solution of EDC in PBS was added to the tissue for 15
min followed by a 3 × 3 min wash with PBS.
For ex vivo labeling of EGFR, unfixed slides were incubated
with 75 :L of a 20 nM solution of Alexa Fluor 555 conjugated
anti-EGFR antibody at room temperature for 25 min followed
by a 3 × 3 min wash with PBS. The anti-mouse CD31 antibody
was imaged in a similar manner. For integrin staining, slides
were incubated at room temperature for 25 min with 75 :L of a
20 nM solution of a primary anti-"v$3 antibody (R&D Systems;
Cat. No. MAB 3050), followed by a 3 × 3 min wash in PBS, 15
min incubation in 75 :L of a 40 nM solution of the secondary
anti-rabbit-TRITC (Sigma–Aldrich; Cat. No. T6778), 3 × 3 min
wash, and imaged. JACoP,54 a plug-in in FIJI, was used to
analyze the in vivo and ex vivo labeling and generate a Pearson
correlation coefficient.
For quantitative image analysis, 5–10 regions of inter-
est were drawn around areas of tumor or liver samples for
injected and uninjected mice imaged with identical settings on
a confocal microscope (to minimize tissue thickness artifacts).
The average intensity of injected samples was first compared
to the uninjected controls to ensure we could measure the sig-
nal above background (verified by T-test of p < 0.05 for all
samples), and then the signal was background subtracted. The
values of at least three animals were compared between tissue
samples for the reported results. For the Pearson correlation
coefficients, individual values were calculated for a minimum
of five images from each tumor and averaged.
Plasma Clearance
Plasma clearance studies of the drugs were conducted
on C57BL/6J mice (Jackson Laboratory). Hoechst 33258
(480 nmol), fluorescently labeled cetuximab (0.2 nmol), and
BODIPY-FL propionic acid (50 nmol) were dissolved in 75 :L
of PBS and injected intravenously via the tail vein. Samples
were obtained retro-orbitally or from the saphenous vein using
heparin coated capillary tubes. Ten microliters of the blood was
mixed with 20 :L of PBS–EDTA and centrifuged to remove
cells. Plasma was pipetted into a 384-well plate, and the signal
was measured on the SpectraMax M5 plate reader for Hoechst
33342 (excitation 350 nm and emission 450 nm) and BODIPY-
FL (excitation 500 nm, emission 515 nm) fluorescence or Licor
Odyssey for cetuximab fluorescence in the 800 nm channel (Fig.
S4, Supporting Information) with a dilution series and plasma-
only samples for background subtraction and quantification.
RESULTS
Table 1 displays the experimentally measured properties of the
drugs and imaging agents used in this study. The molecules
display a wide range in pharmacokinetic parameters and spec-
trally distinct fluorescence to enable independent tracking
within the same tumor microenvironment. BODIPY-FL, ce-
tuximab, and Hoechst 33258 plasma clearance was measured,
and Hoechst 3334255 and Integrisense 68050 values were taken
from the literature. The majority of BODIPY-FL propionic acid
is cleared from the blood within 5 min and does not bind to a
specific target, so the agent was injected 2 min before excising
the tumor to capture differences in blood flow. The BODIPY-
FL dose distributed in a 1.4 mL plasma volume would give an
initial concentration of 35 :M, but the measured concentra-
tion at 1 min was closer to 5 :M. This indicates that signifi-
cant redistribution occurred during the first minute between
the tail vein injection and retro-orbital blood sample. Fluo-
rescently tagged cetuximab distributed similar to unlabeled
cetuximab,56,57 indicating that the low degree of labeling (av-
erage of 1.4 dyes/antibody) had little impact on the plasma
clearance over 1 day.
For the mathematical simulations, the full Krogh cylinder
model simulates individual vessels within a tumor with gradi-
ents around the vessel (radial direction) and along the length
of the vessel (axial direction) (Fig. 1). In a tumor, slow blood
flow depletes small molecules along the length of the vessel as
seen with BODIPY-FL. The small size (<300 Da) and moderate
lipophilicity (predicted log P = 3 and log D = −1) causes the
molecule to distribute quickly in the radial direction. However,
the local plasma concentration is quickly depleted resulting in
low uptake. This is in contrast to liver tissue. Here, higher
blood flow reduces depletion along the length of the vessel
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Table 1. Physiochemical and Optical Properties of Drugs and Imaging Agents
Target Molecular Weight (Da) Ex/Em (nm)
Plasma Protein
Binding (%)
Plasma Clearance (" Fraction, "
Half-Life, $ Half-Life)
Bodipy FL None 292 502/511 89.7 (±3.8) 56.2% alpha
2.6 min
30.37 min
Cetuximab + AF 750 EGFR ∼153,000 752/780 NA 58% alpha
3.0 h
70.3 h
Hoechst 33342 DNA 452 352/455 99.3 (±0.4) 99.5% alpha
2 min
1 h
Hoechst 33258 DNA 424 352/455 98.8 (±0.9) 98.7% alpha
1.3 min
3.0 h
Integrisense 680 Integrins ("V$3) 1432 675/693 94.9 (±2.3) 92.3% alpha
6 min
3.5 h
Figure 1. Simulations based on a Krogh cylinder model with axial and radial gradients (a). Four different agents were simulated with their
predicted class of behavior show in parentheses. The results for BODIPY-FL in tumors (b) and liver (c) demonstrate axial blood flow limitations.
Themonoclonal antibody cetuximab has slow extravasationwith rapid perivascular binding (d). The high plasma protein binding of Hoechst 33342
diminishes axial gradients, whereas slow diffusion into the tissue and rapid cellular uptake results in perivascular distribution (e). Integrisense
680 was simulated at a saturating dose, which results in no transport limitations and uptake equivalent to the receptor concentration (f).
giving much higher uptake (Fig. S5, Supporting Information).
Antibodies such as cetuximab-AF750 have a permeability that
is several orders of magnitude lower than small molecules, so
the slow rate of extravasation does not deplete the concentra-
tion along the length of the vessel. Extravasation limits up-
take, and the molecules that do reach the tissue quickly bind
their target and are immobilized. This results in a perivascu-
lar distribution (Fig. 1). Hoechst 33342 also lacks a significant
gradient along the length of the blood vessel. Although this is
a small molecule like BODIPY-FL, it has much higher plasma
protein binding. Binding to albumin and other proteins occurs
on the millisecond time scale,58 so as free drug extravasates,
bound drug dissociates from proteins to replace it. Although
89.7% of BODIPY-FL propionic acid bound to plasma proteins
versus 99.3% of Hoechst 33342 bound does not appear to be a
large difference, it is the free drug that matters. The ratio of
free drug (10.3% unbound BODIPY-FL versus 00.7% unbound
Hoechst 33342) results in∼15-fold more free drug for BODIPY-
FL. Like cetuximab, the large number of DNA binding sites per
cell quickly immobilizes Hoechst 33342 before it diffuses deep
in the tissue, resulting in a perivascular distribution. Finally,
Integrisense 680 lacks both radial and axial gradients as it
saturates its receptor. In the simulation, a constant receptor
concentration is assumed. The large dose of Integrisense rel-
ative to the low (∼104 receptors/cell) "v$3 expression in A-431
cells saturates the receptor within 30 min. The simulations for
the other agents are shown at the time of tumor excision (2 min
for BODIPY-FL, 24 h for cetuximab, and 3 h for Hoechst 33342),
but it is shown at saturation after 30 min for Integrisense. At
longer times, this agent is internalized and trapped while it
clears from the background.
To compare the simulation predictions with experimental
results, the distribution of these same agents under the same
conditions was measured in tumor xenografts. Macroscopic
(stitched) images of the entire tumor were used to reconstruct
the distribution of all four agents throughout the whole tu-
mor (Fig. 2). The BODIPY-FL signal is 14.7 times higher in
the liver than the tumor (p < 0.005, Fig. S5, Supporting Infor-
mation). This is consistent with the model predictions where
much higher blood flow rates occur in the liver.39 Cetuximab
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Figure 2. High-resolution multichannel fluorescence images were stitched together to generate a whole tumor image. BODIPY-FL and Inte-
grisense 680 show more dispersed signal, whereas cetuximab-AF750 and Hoechst 33342 have a perivascular distribution in agreement with
simulations. CD-31 staining was performed ex vivo to highlight all vessels. The uninjected negative control tumor is a merge of all five fluorescence
channels. The yellow box corresponds to images in Figure 3.
Figure 3. Cellular level imaging of the four fluorescent agents in a tumor corresponding to the box in Figure 2. The yellow arrows point to a
vessel that causes prominent Hoechst 33342 staining but no apparent cetuximab staining. Perivascular cetuximab signal was seen only after
increasing the contrast.
demonstrates a perivascular distribution in the tumor and no
detectable signal in muscle that lacks human EGFR. Hoechst
33342 also exhibits a perivascular distribution within the tu-
mor and labels nuclei in the surrounding muscle. Integrisense
680 shows a more uniform signal throughout the tumor, al-
though it is higher in areas composed of macrophages and
lower but detectable on tumor cells (Fig. S9, Supporting In-
formation). CD31 labeling of the slide with an AlexaFluor-555
labeled antibody shows vasculature throughout the tumor and
surrounding muscle. The signal in all images was higher than
autofluorescence from uninjected controls (Figs. 2 and 3 and
Figs. S6, S7, and S8, Supporting Information). The cetuximab
and Integrisense-680 signals in the liver were close to back-
ground, and the Hoechst 33342 signal, limited by large diffu-
sion distances in the tumor, was uniformly bright in all nuclei
with slightly higher intensity (∼two-fold), which is not unex-
pected given the short diffusion distances in liver (data not
shown).
Zooming in from the whole tumor to individual vessels,
the local heterogeneity is more apparent (Fig. 3). BODIPY-
FL cannot be detected easily as it has low tumor uptake and
rapidly distributes, resulting in diffuse signal. Although the
background autofluorescence of uninjected controls is less than
the measured signal in all four channels, the autofluorescence
is highest relative to the probes in the 488 nm channel. Both
cetuximab and Hoechst 33342 show large gradients in signal
around the vessels, with few but distinct examples of mismatch:
both Hoechst 33342 signal without cetuximab (yellow arrow)
and cetuximab signal without Hoechst 33342 (data not shown).
Integrisense 680 shows a more diffuse fluorescence consistent
with saturated binding sites.
Hoechst 33342 uptake into cells is rapid, staining nuclei
in seconds to minutes. Hoechst 33258, however, takes much
longer to enter cells.59 The nuclei reached saturation within
15 min with Hoechst 33342 but required over 2 h in Hoechst
33258 (Fig. S2, Supporting Information). Rapid cell uptake
is predicted to quickly immobilize Hoechst 33342 near ves-
sels, which can be seen at the macroscopic and vessel level
(Fig. 4). The slower cell uptake of Hoechst 33258 is predicted
to yield a more homogeneous distribution as the drug dif-
fuses farther into the tissue before entering cells and bind-
ing DNA. At 5 min after injection, the Hoechst 33258 has not
had time to diffuse deeper into the tissue and exhibits the
same perivascular staining asHoechst 33342 (with lower inten-
sity, Fig. S10, Supporting Information), but by 3 h the pattern
changes. The overall tumor distribution and vessel level images
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Figure 4. Images and simulations for Hoechst 33342 (top row) and Hoechst 33258 (bottom row). Macroscopic whole tumor images (left) show
strong perivascular distribution of Hoechst 33342, whereas Hoechst 33258 displays a more even staining throughout the tumor. The signal
intensity is much higher for Hoechst 33342 than Hoechst 33258, so the confocal settings and window leveling are different between the images.
Higher resolution images (center) more clearly illustrate nuclear staining of perivascular cells for Hoechst 33342 with even staining for Hoechst
33258. Both dyes have a large increase in fluorescence when bound to DNA, so only the nuclear signal is apparent. Cellular uptake and binding
rates were measured in vitro (Fig. S2, Supporting Information) and entered into the simulation. The radial plots predict rapid uptake and DNA
binding relative to diffusion for Hoechst 33342 (top) versus cellular uptake slower than diffusion for Hoechst 33258 resulting in lower and more
even concentrations.
capture this more uniform labeling, although the absolute sig-
nal intensity remains lower for Hoechst 33258 than Hoechst
33342.
Integrisense 680 has a more uniform but faint distribution
throughout the tumor. In regions primarily consisting of A-431
cells, it has a reasonably high correlation coefficient with ex vivo
anti-"v$3 labeling (Fig. 5). However, there is also a significant
signal in tumormacrophages. Based on estimates of pinocytosis
in macrophages,60 the signal in macrophages from fluid phase
uptake is ∼70% higher than the low (∼104 receptors/cell) "v$3-
expression of A-431 cells. In addition, the Integrisense can bind
to integrins on the macrophages.
The cetuximab staining shows a perivascular pattern when
targeted in vivo (Fig. 5). Ex vivo labeling of the slide with a
noncompetitive antibody shows significantly more EGFR far-
ther from the vessels that was not targeted by the probe. The
resulting Pearson correlation coefficient between these two im-
ages is lower as a result.
DISCUSSION
Drug distribution in tumors is difficult to study due to the
heterogeneity in the physiology/tumor microenvironment com-
bined with the effects of drug properties. The variability in-
cludes both intra- and intertumor tissue heterogeneity as well
as temporal changes. To parse out the effect of drug proper-
ties on tumoral distribution, we used multichannel imaging
within the same tumor to study the distribution of four different
Figure 5. To conduct quantitative image analysis for a comparison
with the simulations, tumor sectionswere labeled ex vivowith anti-"v$3
(top middle) or anti-EGFR (bottom middle) AlexaFluor 555 antibody
and compared with the in vivo signal (left). The Pearson correlation
coefficient was high (0.63) for Integrisense 680, in agreement with the
predicted saturating dose and lack of transport limitations. The cor-
relation coefficient was lower (0.33) for cetuximab in agreement with
predictions. The monoclonal antibody is limited by low permeability,
and rapid binding immobilizes the high affinity antibody near the ves-
sels. The Pearson correlation coefficients are based on average values
for five regions within the tumor.
agents in the same tumor microenvironment. The imaging was
paired with PDE simulations of these agents to compare the
theoretical distribution with the experimental results. Overall,
there was excellent agreement with the theoretical predictions
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for all five simulated agents that varied in molecular weight,
target specificity and expression, plasma clearance, and protein
binding. The model is therefore capable of quickly and inexpen-
sively investigating the impact of drug and tumor properties on
distribution.
This PDE model predicts four broad classes of pharma-
cokinetic distribution in tumors (Fig. 1). By incorporating
blood flow, extravasation, diffusion, and local binding and
metabolism, a wide range of agents can be simulated and com-
pared. This is in contrast to many models that make simpli-
fying assumptions that limit the type of molecule that can be
examined. By incorporating all the major steps in delivery to
the tissue, the simulations are much more broadly applicable,
and no simplifying assumptions need to be made a priori.42 The
first class is blood flow limited agents. This class includes many
small molecules that have low plasma protein binding, so they
have a large free fraction that rapidly extravasates across the
vessel wall and quickly diffuses through the tissue (no diffusion
limitations). Examples of this type of agent include many small
molecules in healthy tissue.35 Here, the nonspecific uptake is
based on lipophilic distribution in the tissue. This is linear
with drug log P values and tissue lipid content,61 and there-
fore it never saturates (unlike class IV). The short diffusion
distances result in few to no interstitial transport limitations
(unlike class III), and the small size allows rapid extravasa-
tion (unlike class II). The result is that the agents are blood
flow limited, and compartmental models use this assumption
in their development.35
Large molecules like biologics have limited extravasation
between the endothelial cells, resulting in permeability limited
uptake. This can be seen in validatedmodels for biologics.39,40,45
Here, compartmental models assume extravasation as the rate-
limiting step, and these models focus on exchange between
the tissue and vascular system based on convective and dif-
fusive mechanisms. For tumors, elevated interstitial pressure
results in diffusive uptake being the dominant mechanism,62,63
but healthy tissue has significant convective extravasation and
lymphatic drainage.64 The heterogeneity often seen with anti-
bodies can be captured with this PDEmodel. The heterogeneity
results from rapid binding relative to interstitial transport (dif-
fusion) and not directly because of low permeability. Cetuximab
rapidly binds to the millions of receptors on the A-431 cells be-
fore it can diffuse away from the vessel. Only after the cells
adjacent to the vessel are saturated do the antibodies diffuse
deeper into the tissue. Internalization andmetabolism by these
cells may permanently prevent this from occurring.65 Lower
affinity antibodies can dissociate and diffuse farther in the tis-
sue resulting in more homogeneous distribution,66,67 although
the rate-limiting step in uptake is still extravasation.
Diffusion limited drugs are often the least reported in the
literature. These agents cannot be easily simulated with com-
partmental models due to the spatial gradients that develop in
the tissue.68 A typical class III agent is a small molecule (that
can extravasate quickly, unlike class II) with high plasma pro-
tein binding (which buffers the free drug concentration along
the length of a capillary, preventing class I designation). It may
also have a nonsaturable mechanism of localization (e.g., high
uptake in membranes) or high target expression (DNA binding
of Hoechst dyes), so it is not limited by binding or metabolism.
Unlike other classes that may be either homogeneous or hetero-
geneous in tissue, this molecule will display spatial gradients
within the tissue.
The final class of agent, class IV or binding and metabolism-
limited agents, cannot be generalized based on their physio-
chemical properties and can encompass small molecules and
macromolecules with widely varying properties. These agents
saturate their binding sites with additional probe that lacks
free target to engage (or enzyme for activation60). With no more
targets (binding site limited), the extra probe intravasates back
into the blood. Because of this, the uptake in a particular tis-
sue is correlated with the number of targets, which is ideal
for imaging agents. For Integrisense, a low number of targets
gave a low overall signal, and increasing the number of "v$3
binding sites in the tissue results in much higher uptake in the
tissue.50 This intuitive result is not always the case for other
agents such as antibodies.24 Therefore, class IV agents are ideal
for quantitative imaging.
Multichannel imaging allows the direct observation of dis-
tribution of multiple agents within the same tissue (Fig. 2).
By stitching together images taken at high resolution, the pat-
tern of uptake across the entire tumor could be reconstructed.
Comparing different drugs in the same tissue, the differences
can be directly attributed to drug properties and not variabil-
ity in the tumor microenvironment, strengthening the conclu-
sions. BODIPY-FL was chosen as a class I agent due to its
small size, relatively low plasma protein binding (for a fluo-
rophore), and green fluorescence which did not interfere with
the other three agents. Blood flow rates to the liver are ap-
proximately fivefold to 10-fold higher than to tumors,39,69,70
and this gives rise to hypoxia in A-431 tumors in particular.71
The higher reported blood flow velocities in liver tissue (70–
500 :m/s72,73) relative to tumors (20–200 :m/s74) resulted in
higher predicted uptake in the liver than in the tumor, which is
in agreement with our experimental observations. Cetuximab-
AF750 extravasated from functional vessels and gave a perivas-
cular pattern of uptake typical of high affinity biologics against
highly expressed targets.21,75,76 Hoechst 33342 has a high level
of plasma protein binding (99.3%), so it fills the functional ves-
sels within the tumor without significant depletion and has pre-
viously been used as ameasure of perfused vessels.47,48 This can
be seen by comparing CD31 staining with Hoechst 33342 and
cetuximab-AF750, where several CD31 stained vessels show a
complete lack of Hoechst or cetuximab staining indicating the
vessel had collapsed prior to injection of any of the agents. Inte-
grisense 680 had staining throughout the tumor and lacked the
perivascular pattern of cetuximab-AF750 and Hoechst 33342.
The large dose injected relative to the low target expression
(∼104 receptors/cell) resulted in a saturation of the binding
sites and a more even distribution. Experimentally, this group
of agents could be used in conjunction with radiolabeled probes.
By combining the fluorescent agents with autoradiography of
an imaging agent or tritiated therapeutic, a comparison can
be made between the new probe and the known fluorescent
agents. This can help parse out the distribution of the radio-
labeled agent due to target interaction versus the local tumor
microenvironment.77,78
Using the high-magnification images, the pattern around in-
dividual vessels could be examined (Fig. 3). Within the tumor,
little BODIPY-FL could be distinguished from background, al-
though the average signal was statistically higher than nega-
tive (uninjected) control tumors (p < 0.01). Any probe enter-
ing the tumor quickly diffuses away from the vessel. Although
we used a cross-linking agent to covalently fix the molecule
to the tissue, some of the drug may have washed away before
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it reacted. The liver uptake was high enough that even with
these limitations, the signal was still statistically significantly
higher than the tumor for this blood flow limited agent. The In-
tegrisense 680 signal is much higher than background (due to
target binding and lower autofluorescence in this channel) and
stains cells throughout the tumor, both consistent with model
predictions.
Comparing the cetuximab-AF750, Hoechst 33342, and CD31
staining, there are some CD31 vessels that stain for only ce-
tuximab or Hoechst 33342. Unlike CD31 vessels that lack both
probes and are likely collapsed, staining of only one compound
shows that it was functioning at some point during the experi-
ment. Transient blood flow in tumor vessels is a well-known
phenomenon where the disrupted pressure gradients result
in transient cessation and even reversal of flow.79 Cetuximab-
AF750 was injected 24 h prior to sacrifice, whereas Hoechst
33342 was injected 3 h beforehand. It is therefore not un-
expected that some vessels would stain with the cetuximab-
AF750 and then stop functioning at some point before the injec-
tion ofHoechst 33342.However, because the antibody is present
the entire time Hoechst 33342 is in the blood, vessels that stain
only with Hoechst 33342 are not expected. The likelihood of a
vessel not functioning for the 21 h between the injections and
then suddenly functioning for a few minutes after the Hoechst
33342 injection (where the majority of uptake occurs before its
rapid clearance) is also low. This has been seen in other tumor
models with trastuzumab and DIOC7 as a vascular stain.75
This is unlikely, however, only if blood flow and the injections
are independent events. The injection itself, either the probe
or agents in the formulation, can alter blood pressure and tu-
mor blood flow,80 resulting in induced changes in blood flow
patterns. If the contrast is increased on the cetuximab-AF750,
there is staining around the vessels that initially appear to
be stained only with Hoechst 33342 indicating that there was
antibody in these vessels when they were delivering Hoechst
33342. Therefore, we hypothesize that the injection of Hoechst
altered the tumor blood flow, resulting in these patterns and
consistent with transient blood flow and model predictions.
Despite the established use of Hoechst 33342 to stain func-
tional vessels in tumors, the kinetic rates of uptake have
not been measured in much detail.52,53 It has also been re-
ported that the uptake of a very similar dye, Hoechst 33258, is
much slower. However, reliable rates of cellular uptake have
not been reported in the literature, and the distribution of
Hoechst 33258 has not been analyzed in vivo. Different modes
of binding and diffusion have been postulated for biologics and
nanoparticles,33,81 and we wanted to see if small molecules fol-
low the same patterns. The modes include fast or slow binding
and fast or slow dissociation. High-affinity antibodies exhibit
fast association and slow release resulting in a binding site
front or barrier,82,83 and it appears Hoechst 33342 follows this
pattern of quickly entering the cell, binding the target, and
dissociating slowly. However, if Hoechst 33258 entered cells
at a rate much slower than diffusion through the tissue, then
it would distribute more homogeneously before entering the
cells (effectively immobilized) and binding to the DNA. Given
the lack of data in the literature, we quantified cellular uptake
rates in A-431 cells for an accurate comparison. In vitro cell cul-
ture experiments showed saturation after 15 min with Hoechst
33342 versus 2 h with Hoechst 33258, and the modeling data
indicated that the Hoechst 33258 would distribute more ho-
mogeneously (albeit at a lower concentration per cell, Fig. 4).
After injecting the same dose, this was exactly what was ob-
served in vivo. We could not quantitatively compare the images
as the intensity differences were too great to image both at the
same microscopy settings. However, qualitatively, the pattern
and intensity were consistent with predictions (Fig. 4). This ex-
ample, where simply switching an ethoxy group to a hydroxyl
group results in such a drastic change in distribution, is one
reason why predictions based exclusively on structure (and no
in vitro data) remain challenging. This also provides an exam-
ple where modeling helps explain a counter-intuitive situation
where rapid cell uptake results in poor distribution and poor
cell uptake yields a more homogeneous distribution.
The modeling for the Hoechst dyes required a separate code
to accurately simulate the distribution. The code used previ-
ously for antibodies56 and small molecules31,42 was based on a
simplifying assumption for diffusion. Antibodies do not cross
cell membranes, so diffusion occurs exclusively in the extracel-
lular space, and the other small molecules crossed cell mem-
branes fast enough to equilibrate between the intracellular
and extracellular space relative to diffusion. The Hoechst dyes
straddled these two extremes where the cellular uptake rate
was on the same time-scale as diffusion in the tissue. There-
fore, the cellular uptake rate had to be explicitly modeled in the
equations (Fig. 4 and Supplemental Section 1).
For Integrisense 680, modeling predictions indicated the
dose was much higher than necessary for saturation, and a low
level of uptake was expected throughout the tumor. In regions
primarily consisting of A-431 cells, the Pearson correlation co-
efficient between the intravenously delivered Integrisense-680
and its target (ex vivo stained "v$3) is 0.63. This high correlation
is expected for a receptor saturated with a probe.65 However, in
tumor macrophages detected with an anti-Mac3 antibody, the
Integrisense 680 signal is slightly higher than on A-431 cells
(Fig. S9, Supporting Information). Our initial hypothesis was
that "v$3 binding sites on activated macrophages84 caused the
higher uptake. However, a cross-reactive "v$3 antibody (bind-
ing both human and mouse integrin) failed to stain these cells.
Alternatively, we calculated whether fluid phase uptake would
be sufficient for the higher macrophage signal. Although par-
ticle shape,16 surface coatings,85,86 and size87,88 affect uptake,
even PEGylated molecules that have low surface interaction
are taken up by these cells.22 Using a previous estimate of fluid
phase uptake by macrophages,60 the predicted concentration
from nonspecific fluid phase uptake was twice that of the bind-
ing to A-431 cells. Therefore, we believe fluid phase uptake
contributes to the higher macrophage than A-431 cell signal,
but local binding or fluid phase uptake are both consistent with
a lack of transport limitations and class 4 distribution.
Cetuximab-AF750 is limited by extravasation based on pre-
vious reports.15,42 The dose used was sub-saturating, so for
this high affinity antibody, only cells adjacent to blood ves-
sels were labeled. This results in a lower Pearson correlation
coefficient between intravenously delivered cetuximab and ex
vivo ant-EGFR labeling. A larger dose would saturate all the
binding sites24 and result in a more homogeneous distribution
(and higher Pearson correlation coefficient) as shown in tumor
spheroids65 and xenografts.21,89
One of the biggest hurdles to using mathematical models
in research is the extensive effort required to develop a model
and parameterize all the rates. Although software exists for
compartmental models, the assumptions for these models are
sometimes valid and other times inaccurate.90 To facilitate the
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use of this PDE model that does not have these limitations, we
generated a graphical user interface (GUI) for the simulations
(Fig. S3, Supporting Information). This allows a user to quickly
simulate a wide range of agents, from small molecules to bio-
logics and nanoparticles, without coding. The tumor physiology
parameters can also be varied to study the impact on distri-
bution in a matter of seconds, facilitating the use of the model
for experimental predictions. This code can be used in design-
ing experiments and interpreting in vivo data for new agents
or tissues by modifying the parameters according to litera-
ture published values and correlations (Table S1, Supporting
Information).
CONCLUSIONS
We have used multichannel imaging of four agents in a tu-
mor and compared the distribution to a PDE model. The
model distinguishes four different rate-limiting steps in uptake
with practical applications such as imaging agent development
or combination therapies that normalize the vasculature,1,91
which may have synergistic or antagonistic effects. Together,
a combined theoretical and experimental approach can help
in designing more focused animal experiments, interpreting in
vivo results, and developing improved therapeutics and imag-
ing agents.
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